A Phase 3 clinical trial titled "Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen" was listed with recruiting status as of August 4, 2026. The trial, registered under identifier NCT07087054, is evaluating an oral daily regimen of paltusotine in patients with carcinoid syndrome. This is a Phase 3 study, indicating a later stage clinical investigation. The current status of the trial is recruiting, meaning participant enrollment is underway.
Paltusotine is being studied in the context of carcinoid syndrome, a condition also addressed by somatostatin analogs such as lanreotide, which remains an approved therapy. No results or outcome data have been reported for this trial at this stage. The listing reflects only the trial's design, phase, and current recruitment status as registered.
Further updates on this study may become available as recruitment progresses and as the trial advances through its phases. Readers interested in background on lanreotide and its approved uses can consult the compound overview for additional context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07087054"]